A need for a simplified approach to venous thromboembolism prophylaxis in acute medical inpatients

International Journal of Clinical Practice

Volumn 61, Issue 2, 2007, Pages 336-340

  Howard, Dominic P J ^a,b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EMERGENCY CARE; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HOSPITALIZATION; HUMANS; MEDICAL AUDIT; PRACTICE GUIDELINES; PULMONARY EMBOLISM; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33847057674     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00863.x     Document Type: Article

References (28)

1. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-11.
2. Sandler DA, Martin IF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5.
3. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71.
4. Belch JJ, Lowe GDO, Ward AG et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-7.
5. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
6. Callam M. Prevalence of chronic leg ulceration and severe chronic venous disease in western countries. Phlebology 1992; 7 (Suppl. 1): 6-12s.
7. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ) 2001; i-x: 1-668.
8. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl.): 132S-175S.
9. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-9.
10. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004; (3): Art. No.: CD 000024. Doi: 10.1002/14651858.CD000024.pub2
11. Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO . International Society and Federation of Cardiology Task Force. JAMA 1992; 268: 1727-33.
12. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. American Heart Association. Circulation 1994; 89: 1449-68.
13. Second THRiFT Risk Factors Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998; 13: 87-97.
14. Nicolaides AN, Arcelus J, Belcaro G et al. Prevention of venous thromboembolism. European Consensus Statement, developed at Oakley Court Hotel, Windsor, UK. Int Angiol 1992; 11: 151-9.
15. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (Suppl.): 312S-334S.
16. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 338S-400S.
17. Ageno W, Squizzato A, Ambrosini F et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-50.
18. Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-6.
19. Vallano A, Arnau JM, Miralda GP, Perez-Bartoli J. Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thromb J 2004; 2: 3.
20. Nicolaides AN, Breddin HK, Fareed J et al. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
21. Scottish Intercollegiate Guidelines Network. Prophylaxis of Venous Thromboembolism. A National Clinical Guideline 2003.
22. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9. Epub 2004 August 02.
23. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-9.
24. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 561-5.
25. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347: 1357-61.
26. Lamy A, Wang X, Kent R, Smith KM, Gafni A. Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical patients with Enoxaparin. Can Respir J Jun 2002; 9: 169-77.
27. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. Second Report of Session 2004.05. London: The Stationary Office Ltd, March 2005.
28. Department of Health. Government response to the house of commons health committee report on the prevention of venous thromboembolism in hospitalised patients . Second Report of Session 2004.05. London: The Stationary Office Ltd, July 2005.